TTD of global heath (hazard ratio [HR 0.41]), physical functioning (HR 0.52), and role functioning (HR 0.58) with 177 Lu-Dotatate compared to high-dose octreotide. With respect to symptoms, there was significant improvement in TTD of diarrhea (HR 0.47), pain (HR 0.57), fatigue (HR 0.62) among other symptoms. There were no domains where improvement in TTD was seen with in the control arm [2] .
These results provided an important validation that 177 Lu-Dotatate not only improves progression-free survival (PFS) but also delays decline in quality of life and progression of symptoms. In the future, more randomized clinical trials should employ this emerging methodology to assess the impact of the investigational treatment on HRQoL. Moreover, standardized rules analogous to Response Evaluation Criteria in Solid Tumors (RECIST) should be developed to allow for uniform interpretation of HRQoL data across oncologic clinical trials.
